{"id":"W3209667002","doi":"10.14309/01.ajg.0000776960.58058.bf","title":"S857 Patient-Reported Outcomes of Response and Remission Following Guselkumab Induction Treatment as Measured by the Inflammatory Bowel Disease Questionnaire: Results Through Week 12 of the Phase 2 GALAXI 1 Study","year":2021,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Inflammatory bowel disease; Placebo; Internal medicine; Crohn's disease; Population; Vedolizumab; Clinical endpoint; Randomized controlled trial; Quality of life (healthcare); Randomization; Gastroenterology; Physical therapy; Disease; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002692527,0.0005518008,0.001406131,0.0003221222,0.00021686,0.0005971208,0.0004425312,0.001042873,0.00628125],"category_scores_gemma":[0.001714496,0.0002594953,0.001526943,0.0004022382,0.0003393388,0.000476848,0.0003632793,0.001193765,0.001250076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003046406,"about_ca_system_score_gemma":0.0005677086,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004429498,"about_ca_topic_score_gemma":0.0007111778,"domain_scores_codex":[0.9989642,0.0006332016,0.00007459715,0.00009209735,0.0001426622,0.00009330657],"domain_scores_gemma":[0.9986144,0.0003731647,0.0005553021,0.00009952942,0.0001400274,0.0002175024],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8299186,0.0105371,0.04134702,0.001586802,0.004012655,0.0001139853,0.0001790439,0.000891222,0.00692175,0.0001290046,0.005412168,0.09895068],"study_design_scores_gemma":[0.4278884,0.3038078,0.2542171,0.0002246454,0.003495401,0.0002160995,0.0001036089,0.001303727,0.002421539,0.0002093396,0.006050887,0.00006151687],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882658,0.002867292,0.0004646838,0.0003192102,0.00009075375,0.001202835,0.004127929,0.0000790084,0.002582607],"genre_scores_gemma":[0.9864148,0.001080866,0.000982652,0.0007341,0.00021106,0.001725667,0.005646857,0.00002427302,0.003179745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00628125,"threshold_uncertainty_score":0.0210129,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01122458521306753,"score_gpt":0.2714644685166654,"score_spread":0.2602398833035979,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}